Sulbactam-durlobactam for anti-infection treatment after lung transplantation
10.12464/j.issn.1674-7445.2025175
- VernacularTitle:舒巴坦-度洛巴坦用于肺移植术后抗感染治疗
- Author:
Lulin WANG
1
;
Xiaohua WANG
1
;
Jie ZHANG
1
;
Shouning ZHOU
1
;
Pengjiu YU
1
;
Chunrong JU
1
Author Information
1. 510012 广州,广州医科大学附属第一医院移植科广州呼吸健康研究院
- Publication Type:Journal Article
- Keywords:
Sulbactam-durlobactam;
Lung transplantation;
Infection;
Chronic obstructive pulmonary disease;
Gram-negative bacilli;
Extensively drug-resistant Acinetobacter baumannii;
Meropenem;
Intensive care unit
- From:
Organ Transplantation
2025;16(5):756-762
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the clinical experience of the first case of sulbactam-durlobactam treatment for extensively drug-resistant Acinetobacter baumannii infection after lung transplantation in China.Methods A retrospective analysis was conducted on a case of a patient with severe chronic obstructive pulmonary disease who received sulbactam-durlobactam treatment after lung transplantation.Results A 68-year-old male patient with a history of drug-resistant Acinetobacter baumannii infection before surgery,experienced worsening infection and impaired renal function after lung transplantation,with sputum culture showing extensively drug-resistant Acinetobacter baumannii.After receiving combination treatment with sulbactam-durlobactam and meropenem,the infection was controlled,and the function of the transplanted lung was restored.Conclusions Sulbactam-durlobactam has potential therapeutic value for extensively drug-resistant Acinetobacter baumannii infection after lung transplantation and provides a new strategy for clinical practice.
